摘要
抗叶酸剂MTX被运用于急性成淋巴细胞白血病,非霍奇金淋巴瘤,骨肉瘤,银屑病,类风湿性关节炎等疾病的治疗当中,但在临床上给病人相同剂量的MTX时,病人的反应及毒性的种类也大为不同。这多样性从一定程度上来说和基因的连续变更有关,本文章主要从亚甲基四氢叶酸还原酶(MTHFR)基因,MTX跨膜运输中的两种流出载体基因和MTX新陈代谢相关的四种基因中的单核苷酸多态性(SNP)两方面来阐述MTX在不同病人中出现的不良反应的新进展。
The antifolate methotrexate is widely used in the treatment of acutelymphoblastic leukaemia,non-Hodgkin lymphoma,osteosarcoma,Psoriasis,andRheumatoid Arthritis Even when given identical methotrexate doses,patients vary significantly in their response and pattern of toxicities.This diversity can,to some extent,be linked to sequence variations in genes.This paper mainly talk about the advance of toxicity which is in different patient from the methylenetetrahydrofolate reductase(MTHFR) gene and single nucleotide polymorphisms(SNPs) across four genes that are relevant to methotrexate metabolism and the two efflux transporter genes in methotrexate transmembrane.
出处
《现代生物医学进展》
CAS
2010年第13期2578-2580,共3页
Progress in Modern Biomedicine